OKYO Pharma shares surge 12.13% intraday after Phase 2 trial shows urcosimod's favorable corneal nerve outcomes.

OKYO Pharma surged 12.13% intraday after announcing favorable Phase 2 trial data for urcosimod, showing directional improvements in corneal nerve fiber count and length in neuropathic corneal pain (NCP) patients. The 18-patient, placebo-controlled trial revealed median increases in nerve metrics for the 0.05% urcosimod group, contrasting with declines in the placebo cohort. These findings, described as "biologically meaningful" by the principal investigator, suggest the drug may not only reduce pain but also support corneal nerve restoration, positioning it as a potential first-in-class therapy for NCP, a condition with no FDA-approved treatment. The results reinforce OKYO’s chemerin receptor pathway strategy and pave the way for a larger trial in Q1 2026.